ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES HOW INCENTIVES COULD SUPPORT EFFECTIVENESS RESEARCH OF MEDICAL DEVICES

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this morning on Incentivizing Research Into the Effectiveness of Medical Devices at the Society’s 19th Annual European Congress in Vienna, Austria.  The session was moderated by Rosanna Tarricone, PhD, Professor, Centre for Research on Health and Social Care Management, Bocconi University, Milan, Italy. Speakers for the session included:
  • Michael F. Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
  • Mirella Marlow, MBA, MA, Programme Director, Devices and Diagnostics Systems, National Institute for Health and Clinical Excellence (NICE), London, UK
  • Adrian Griffin, MSc, Vice President, HTA and Reimbursement Policy, Johnson & Johnson, High Wycombe, UK
This issue panel examined how incentives could be utilized to increase the range and quality of effectiveness research of medical devices. Speakers noted that medical devices often gain market authorization with significantly less clinical effectiveness evidence than other health technologies, such as pharmaceuticals, because of the different legal requirements for approval of medical devices. The panel also remarked that post-market effectiveness research may actually be more important for medical devices than pharmaceuticals since the performance of the device often depends on the interaction with the user. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×